{"preliminary_commentary":{"by_channel":{"youtube":15,"podcast":7,"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04188548\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["imlunestrant"],["imlunestrant","abemaciclib"],["imlunestrant","everolimus"]],"indication":"ER+ advanced breast cancer and endometrial cancer","name":"EMBER","nct_id":"NCT04188548","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ember-nct04188548. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EMBER","arms":[{"description":"LY3484356 given orally.","label":"Dose Escalation LY3484356","type":"EXPERIMENTAL"},{"description":"LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.","label":"Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI","type":"EXPERIMENTAL"},{"description":"LY3484356 given orally.","label":"Part B: Dose Expansion: Cohort E3: LY3484356","type":"EXPERIMENTAL"},{"description":"LY3484356 and everolimus given orally.","label":"Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus","type":"EXPERIMENTAL"},{"description":"LY3484356 and alpelisib given orally.","label":"Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib","type":"EXPERIMENTAL"},{"description":"LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.","label":"Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib","type":"EXPERIMENTAL"},{"description":"LY3484356 and Abemaciclib given orally with trastuzumab administered intravenously.","label":"Part D: Dose Expansion: LY3484356 +/- Abemaciclib","type":"EXPERIMENTAL"},{"description":"LY3484356 administered orally in combination with trastuzumab and pertuzumab administered intravenously.","label":"Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12","type":"ESTIMATED"},"conditions":["Breast Cancer","Advanced Breast Cancer","Metastatic Breast Cancer","Endometrial Cancer"],"enrollment":{"count":379,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"LY3484356","otherNames":["Imlunestrant"],"type":"DRUG"},{"name":"Abemaciclib","otherNames":["LY2835219"],"type":"DRUG"},{"name":"Everolimus","otherNames":[],"type":"DRUG"},{"name":"Alpelisib","otherNames":[],"type":"DRUG"},{"name":"Trastuzumab","otherNames":[],"type":"DRUG"},{"name":"Aromatase Inhibitor (AI)","otherNames":[],"type":"DRUG"},{"name":"Pertuzumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-22","lead_sponsor":"Eli Lilly and Company","official_title":"EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2020-06-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities","timeFrame":"Baseline through Cycle 1 (21/28 Day Cycle)"}],"references":[{"citation":"Bhave M, Jhaveri KL, Kaufman PA, Aftimos P, Lombard J, Giridhar KV, Im SA, Ma CX, Lee KT, Kim SB, Sohn J, Li Y, Yuen E, Estrem ST, Nguyen B, Makena MR, Ismail-Khan R, Beeram M. Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study. Breast Cancer Res. 2025 Dec 21;28(1):18. doi: 10.1186/s13058-025-02168-6.","pmid":"41423595","type":"DERIVED"},{"citation":"Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, Bhave M, Kaufman PA, Beck JT, Manso Sanchez L, Parajuli R, Wang HC, Tao JJ, Im SA, Harnden K, Yonemori K, Dhakal A, Neven P, Aftimos P, Pierga JY, Lu YS, Larson T, Jerez Y, Sideras K, Sohn J, Kim SB, Saura C, Bardia A, Sammons SL, Bacchion F, Li Y, Yuen E, Estrem ST, Rodrik-Outmezguine V, Nguyen B, Ismail-Khan R, Smyth L, Beeram M. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. J Clin Oncol. 2024 Dec 10;42(35):4173-4186. doi: 10.1200/JCO.23.02733. Epub 2024 Sep 6.","pmid":"39241211","type":"DERIVED"}],"start_date":{"date":"2019-12-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","url":"https://clinicaltrials.gov/study/NCT04188548"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ember-nct04188548"}